Literature DB >> 12000706

Bcl-2 expression inhibits liver carcinogenesis and delays the development of proliferating foci.

Robert H Pierce1, Mary E Vail, Leah Ralph, Jean S Campbell, Nelson Fausto.   

Abstract

Tumor development is thought to require both increased proliferation and inhibition of apoptosis. However, the relationship between cell replication and cell death in liver tumorigenesis is complex because both proliferation and apoptosis increase during hepatocarcinogenesis. To investigate the effect of the anti-apoptotic gene Bcl-2 in liver carcinogenesis, we established a line of double transgenic mice that express transforming growth factor-alpha (TGF-alpha), a liver mitogen, and Bcl-2. Double transgenic mice, TGF-alpha and Bcl-2 single transgenics, and wild type received an injection of diethylnitrosamine at 15 days of age. This alkylating agent induces liver carcinogenesis and its effect is greatly enhanced by TGF-alpha. We report that Bcl-2 expression inhibited diethylnitrosamine-induced liver carcinogenesis and counteracted the enhancing effect of TGF-alpha. Bcl-2 delayed the growth of proliferative foci at the early stages of carcinogenesis and inhibited cell proliferation in these foci. The effect of Bcl-2 on liver carcinogenesis is consistent with its reported ability to interfere with cell replication. The data demonstrate that the expression of an anti-apoptotic gene during liver carcinogenesis causes a delay rather than an increase in tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12000706      PMCID: PMC1850870          DOI: 10.1016/S0002-9440(10)61101-7

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  22 in total

1.  The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry.

Authors:  D C Huang; L A O'Reilly; A Strasser; S Cory
Journal:  EMBO J       Date:  1997-08-01       Impact factor: 11.598

2.  High, persistent hepatocellular proliferation and apoptosis precede hepatocarcinogenesis in growth hormone transgenic mice.

Authors:  K J Snibson; P S Bhathal; C L Hardy; M R Brandon; T E Adams
Journal:  Liver       Date:  1999-06

3.  p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients.

Authors:  R Silvestrini; E Benini; S Veneroni; M G Daidone; G Tomasic; P Squicciarini; B Salvadori
Journal:  J Clin Oncol       Date:  1996-05       Impact factor: 44.544

4.  BCL-2 expression correlates with lower proliferative activity in the intermediate- and high-grade non-Hodgkin's lymphomas: an Eastern Cooperative Oncology Group and Southwest Oncology Group cooperative laboratory study.

Authors:  J N Winter; J Andersen; J C Reed; S Krajewski; D Variakojis; K D Bauer; R I Fisher; L I Gordon; M M Oken; S Jiang; D Jeffries; P Domer
Journal:  Blood       Date:  1998-02-15       Impact factor: 22.113

5.  Inherent increase of apoptosis in liver tumors: implications for carcinogenesis and tumor regression.

Authors:  B Grasl-Kraupp; B Ruttkay-Nedecky; L Müllauer; H Taper; W Huber; W Bursch; R Schulte-Hermann
Journal:  Hepatology       Date:  1997-04       Impact factor: 17.425

6.  The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry.

Authors:  L A O'Reilly; D C Huang; A Strasser
Journal:  EMBO J       Date:  1996-12-16       Impact factor: 11.598

7.  Inverse correlation between bcl-2 expression and cell growth fraction in human endometrial adenocarcinoma tissue.

Authors:  Y Kuwashima; Y Kobayashi; M Kurosumi; J Tanuma; K Shiromizu; K Kishi
Journal:  Anticancer Res       Date:  1997 Sep-Oct       Impact factor: 2.480

Review 8.  Apoptosis and multistage carcinogenesis in rat liver.

Authors:  R Schulte-Hermann; W Bursch; B Grasl-Kraupp; L Müllauer; B Ruttkay-Nedecky
Journal:  Mutat Res       Date:  1995-12       Impact factor: 2.433

9.  Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma.

Authors:  F A Sinicrope; J Hart; F Michelassi; J J Lee
Journal:  Clin Cancer Res       Date:  1995-10       Impact factor: 12.531

10.  Regulation of cell division cycle progression by bcl-2 expression: a potential mechanism for inhibition of programmed cell death.

Authors:  S Mazel; D Burtrum; H T Petrie
Journal:  J Exp Med       Date:  1996-05-01       Impact factor: 14.307

View more
  32 in total

Review 1.  c-Myc induction of programmed cell death may contribute to carcinogenesis: a perspective inspired by several concepts of chemical carcinogenesis.

Authors:  Chenguang Wang; Yanhong Tai; Michael P Lisanti; D Joshua Liao
Journal:  Cancer Biol Ther       Date:  2011-04-01       Impact factor: 4.742

2.  Decreased aquaporin expression leads to increased resistance to apoptosis in hepatocellular carcinoma.

Authors:  Elizabeth M Jablonski; M Adrian Mattocks; Eugene Sokolov; Leonidas G Koniaris; Francis M Hughes; Nelson Fausto; Robert H Pierce; Iain H McKillop
Journal:  Cancer Lett       Date:  2006-11-03       Impact factor: 8.679

3.  Hepatocyte-specific Bid depletion reduces tumor development by suppressing inflammation-related compensatory proliferation.

Authors:  A Wree; C D Johnson; J Font-Burgada; A Eguchi; D Povero; M Karin; A E Feldstein
Journal:  Cell Death Differ       Date:  2015-04-24       Impact factor: 15.828

4.  Effect of 5-aminolevulinic acid on the expression of carcinogenesis-related proteins in cultured primary hepatocytes.

Authors:  P R Menezes; C B González; A O DeSouza; D A Maria; J Onuki
Journal:  Mol Biol Rep       Date:  2018-09-14       Impact factor: 2.316

5.  PUMA-mediated apoptosis drives chemical hepatocarcinogenesis in mice.

Authors:  Wei Qiu; Xinwei Wang; Brian Leibowitz; Wancai Yang; Lin Zhang; Jian Yu
Journal:  Hepatology       Date:  2011-10       Impact factor: 17.425

Review 6.  How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression?

Authors:  Brandon J Aubrey; Gemma L Kelly; Ana Janic; Marco J Herold; Andreas Strasser
Journal:  Cell Death Differ       Date:  2017-11-17       Impact factor: 15.828

7.  Serine threonine kinase Pim-3 regulates STAT3 pathway to inhibit proliferation of human liver cancers.

Authors:  Jianqiang Wang; Lijun Lao; Hui Zhao; Yuan Huang
Journal:  Int J Clin Exp Med       Date:  2014-02-15

8.  G0 function of BCL2 and BCL-xL requires BAX, BAK, and p27 phosphorylation by Mirk, revealing a novel role of BAX and BAK in quiescence regulation.

Authors:  Yelena Janumyan; Qinghua Cui; Ling Yan; Courtney G Sansam; Mayda Valentin; Elizabeth Yang
Journal:  J Biol Chem       Date:  2008-09-25       Impact factor: 5.157

9.  Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis.

Authors:  Toshiharu Sakurai; Guobin He; Atsushi Matsuzawa; Guann-Yi Yu; Shin Maeda; Gary Hardiman; Michael Karin
Journal:  Cancer Cell       Date:  2008-08-12       Impact factor: 31.743

10.  Is there any potential link among caspase-8, p-p38 MAPK and bcl-2 in clear cell renal cell carcinomas? A comparative immunohistochemical analysis with clinical connotations.

Authors:  Vassilis Samaras; Maria Tsopanomichalou; Angeliki Stamatelli; Christos Arnaoutoglou; Efstathios Samaras; Marianthi Arnaoutoglou; Hercules Poulias; Calypso Barbatis
Journal:  Diagn Pathol       Date:  2009-02-17       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.